Biomarker-driven clinical trials are critical to advancing precision medicine, yet they often face significant challenges, including slow patient recruitment, complex logistics and high costs. Centralized next-generation sequencing (NGS) testing can exacerbate these issues, delaying the identification of eligible patients and hindering timely enrollment and treatment initiation.
Rapid and decentralized NGS technologies present a promising strategy for addressing these challenges, offering the potential to streamline clinical trials. Decentralized NGS enables testing capabilities closer to patients, reducing the reliance on central laboratories and minimizing the time required for sample transportation and processing.
This approach allows for faster identification of relevant mutations and more efficient patient stratification, leading to improvement in recruitment rates and reduction in trial timelines. Decentralized NGS also enhances accessibility for patients in remote or underserved areas, helping to ensure more diverse and representative trial populations. The rapid turnaround time of advanced NGS platforms further accelerates trial workflows, enabling timely molecular data necessary to make informed decisions on patient treatment paths.
In this webinar, the speakers will discuss the transformative role of decentralized NGS in streamlining trial operations. By decentralized NGS testing, clinical trials can significantly reduce reliance on central laboratories, thus minimizing delays in sample transportation and processing and enabling faster identification of eligible patients.
This webinar will also cover the critical importance of timely genomic profiling in clinical trials. As the identification of relevant mutations can directly impact treatment decisions, the rapid turnaround time of an advanced NGS platform enables investigators with crucial information for timely and informed decisions.
Register for this webinar today to understand how decentralized next-generation sequencing testing reduces reliance on central laboratories and minimizes time required for sample transportation and processing.
Speakers
Jane Li, Senior Director, Pharma and CRO, Life Sciences Solutions Group, Thermo Fisher Scientific
Jane Li has been serving as Senior Director, Global Companion Diagnostics for Clinical Next-Generation Sequencing at Thermo Fisher Scientific since 2015. She leads the development and commercialization of companion diagnostics, driving innovation at the intersection of genomics and precision oncology.
Previously, she was Senior Director, Clinical and Pharma Services for Clinical Next-Generation Sequencing and she also held different roles in corporate strategy, business development and M&A over the past 20 years at with Thermo Fisher Scientific.
Message Presenter
Dr. Binh Nguyen, VP, Medical Science and Strategy, Clinical Research, Thermo Fisher Scientific
Dr. Nguyen is Vice President, Medical Science and Strategy – Oncology, with 30 years of experience in oncology clinical development in the pharmaceutical/biotech industry. He provides medical and strategic guidance to the oncology product development strategy team and clinical trial design as well as regulatory guidance to clients.
Prior to joining PPD in 2015, Dr. Nguyen was VP, Clinical Development at Endocyte, Chief Medical Officer at Tigris Pharmaceutical and Executive Medical Director at Eli Lilly and Co. He also was a Medical Fellow at the Investigational Drug Branch, Cancer Treatment Evaluation Program, NCI, NIH, and Medical Reviewer for INDs and NDAs at the US Food and Drug Administration prior to joining the industry.
Dr. Nguyen holds an MD degree from the University of Maryland School of Medicine and a PhD in Organic Chemistry from Georgetown University in Washington, DC. He completed an oncology fellowship at the NCI, NIH.
Message Presenter
Chris Morris, BSc (Hons), Sr Director, Consulting, Innovation & Strategy, Patient First Digital Solutions, PPD Clinical Research Business of Thermo Fisher Scientific
Chris Morris has over 20 years of experience in clinical research, primarily within clinical operations and project management at various pharmaceutical companies and clinical research organizations. He possesses extensive experience in managing digital and decentralized clinical trials worldwide, showcasing a robust ability to adapt to the evolving landscape of clinical research.
He has led several global clinical trials and has developed expertise across multiple therapeutic indications, including oncology, cardiology, respiratory, rare diseases, general medicine and consumer health. His breadth of experience underlines his capacity to handle complex trials and drive successful outcomes in diverse medical fields. He has a Master’s degree in biomedical science.
Message Presenter
Jacinda Snow, Sr. Director, Project Management, Hematology / Oncology, PPD Clinical Research Business of Thermo Fisher Scientific
Jacinda Snow has over 20 years of working experience in clinical research with a primary focus in Clinical Operations and Project Management. Jacinda has extensive experience in managing complex adaptive trials and serves as an Oversight Director and Portfolio Lead responsible for the execution of 20+ trials with a strategic partner. She is also engaged in the Cell Therapy Center of Excellence within CRG/Thermo Fisher.
Message PresenterWho Should Attend?
This webinar will appeal to those with the following job titles or in the following fields:
- Biotech Researchers
- Biopharma Researchers
- Clinical operations
What You Will Learn
Attendees will learn about:
- The key challenges and complexities with oncology biomarker-driven clinical trials
- Key considerations when managing oncology biomarker-driven trials
- How rapid and decentralized NGS technologies help identify eligible patients and minimize clinical trial delays
Xtalks Partner
The PPD clinical research business of Thermo Fisher Scientific Inc
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, enables customers to accelerate innovation and increase drug development productivity. Utilizing patient-centered strategies and data analytics, their capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, novel approaches to patient recruitment and investigator sites, and comprehensive laboratory services. Recognized as a global industry leader in accelerating promising medicines from early development through regulatory approval and market access, they serve pharma, biotech, medical device and government organizations with custom-tailored solutions, including full-service partnerships and functional service partnerships. As a strategic partner in clinical development and analytical services, they apply cutting edge technologies, therapeutic expertise and a firm commitment to quality to help customers deliver life-changing therapies.
Related Webinars
Fast, Faster, Fastest: Is It Time for Automated Model Building?
Maximizing Patient Recruitment in Rare Neurological Clinical Studies
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account